19.05.2023 • NewsWorleymethanenatural gas

Graforce and Worley to Scale Methane Electrolysis Technology in Asia-Pacific

German hydrogen technology company Graforce and Australian multinational engineering contractor Worley are collaborating to scale methane electrolysis (plasmalysis) in Australia, China and Asia-Pacific.

© Shutterstock
© Shutterstock

Plasmalysis converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or other greenhouse gases. Graforce said plasmalysis requires only one-fifth of the energy to produce the same amount of hydrogen compared to water electrolysis. For example, a single 20-megawatt plant can convert about 70,000 t/y of methane into hydrogen, eliminating about 200,000 t/y of CO2 emissions.

“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Graforce’s founder and chief technology officer Jens Hanke.

Worley will provide engineering and project delivery services for plasmalysis plant customers in Australia and Asia.

Graforce added that the “game-changing” technology allows gas consumers to switch to hydrogen without changing their energy supplier or transportation mode.

Author: Elaine Burridge, Freelance Journalist

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.